Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study

被引：25

作者：

Yamamoto, Kaichtro ^{[1
]}

Kokawa, Katsuji

Umesaki, Naohiko ^{[2
]}

Nishimura, Ryuichiro ^{[3
]}

Hasegawa, Kazuo ^{[4
]}

Konishi, Ikuo ^{[5
]}

Saji, Fumitaka ^{[6
]}

Nishida, Masato ^{[7
]}

Noguchi, Hiroshi ^{[8
]}

Takizawa, Ken ^{[9
]}

机构：

[1] Kinki Univ, Sch Med, Dept Obstet & Gynecol, Sakai Hosp,Minami Ku, Osaka 5900132, Japan

[2] Wakayama Med Univ, Dept Obstet & Gynecol, Wakayama 6410012, Japan

[3] Hyogo Canc Ctr, Dept Gynecol Oncol, Akashi, Hyogo 6738558, Japan

[4] Inamino Hosp, Kakogawa, Hyogo 6750104, Japan

[5] Kyoto Univ, Dept Gynecol & Obstet, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan

[6] Natl Hosp Org, Kure Med Ctr, Hiroshima 7370023, Japan

[7] Natl Hosp Org, Kasumigaura Med Ctr, Tsuchiura, Ibaraki 3008585, Japan

[8] Natl Hosp Org, Matsumoto Med Ctr, Nagano 3998701, Japan

[9] Japanese Fdn Canc Res, Dept Gynecol, Canc Inst Hosp, Koto Ku, Tokyo 1358550, Japan

来源：

ONCOLOGY REPORTS | 2009年 / 21卷 / 04期

关键词：

irinotecan hydrochloride; nedaplatin; phase I study; cervical cancer; squamous cell carcinoma; COLONY-STIMULATING FACTOR; RANDOMIZED-TRIAL; 1ST-LINE CHEMOTHERAPY; CANCER; CISPLATIN; THERAPY; LINES;

D O I：

10.3892/or_00000316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study (JGOG 1063) was to determine the recommended dose (RD) for combination chemotherapy with irinotecan hydrochloride (CPT-11) and nedaplatin (NDP) for advanced cervical squamous cell carcinoma. CPT-11 was given intravenously in fixed doses of 60 mg/m(2) on days I and 8 and NDP, in escalating doses, on day 1, every 4 weeks. A total of 15 patients were enrolled in the study. At level I (NDP: 50 mg/m(2)), one of the 3 patients developed grade 3 diarrhea, so 3 additional patients were enrolled at this level. As none of the 3 additional patients exhibited dose-limiting toxicity, level I was elevated to level 2 (NDP: 60 mg/m(2)). The maximum tolerated dose was not reached, even at the highest dose level (level 4; NDP: 80 mg/m(2)). No further dose escalation was carried out, and level 4 (CPT-11: 60 mg/m(2), NDP: 80 mg/m(2)) was determined as the RD.

引用

页码：1005 / 1009

页数：5

共 17 条

[1] RANDOMIZED TRIAL OF 3 CISPLATIN DOSE SCHEDULES IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].

BONOMI, P ;

BLESSING, JA ;

STEHMAN, FB ;

DISAIA, PJ ;

WALTON, L ;

MAJOR, FJ .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) :1079-1085

[2] Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer [J].

Chitapanarux, I ;

Tonusin, A ;

Sukthomya, V ;

Charuchinda, C ;

Pukanhapan, N ;

Lorvidhaya, V .

GYNECOLOGIC ONCOLOGY, 2003, 89 (03) :402-407

[3]

Kanzawa F, 2001, CLIN CANCER RES, V7, P202

[4]

Kato T, 1992, JPN J CANC CHEMOTHER, V19, P695

[5] Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer [J].

Machida, S ;

Ohwada, M ;

Fujiwara, H ;

Konno, R ;

Takano, M ;

Kita, T ;

Kikuchi, Y ;

Komiyama, S ;

Mikami, M ;

Suzuki, M .

ONCOLOGY, 2003, 65 (02) :102-107

[6]

NGUYEN HN, 1993, INT J ONCOL, V3, P375

[7]

NODA K, 1987, JPN J CANC CHEMOTHER, V14, P1129

[8]

Noda K, 1992, JPN J CANC CHEMOTHER, V19, P885

[9]

Okamoto H, 1998, CANCER, V82, P2166, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2166::AID-CNCR11>3.0.CO

[10]

2-S

← 1 2 →